Actively Recruiting
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2026-03-04
9
Participants Needed
1
Research Sites
521 weeks
Total Duration
On this page
Sponsors
T
The First Affiliated Hospital with Nanjing Medical University
Lead Sponsor
W
Westlake University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells
CONDITIONS
Official Title
Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged between 18 and 75 years old
- Diagnosed with calciphylaxis, including those with chronic kidney disease on or off dialysis
- Provided signed informed consent
You will not qualify if you...
- Refusal to sign informed consent
- Having malignant tumors, severe psychiatric disorders, or expected survival of less than 6 months
- Pregnant or breastfeeding women of childbearing age
- Participation in another clinical trial with an experimental drug within the past 90 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital
Nanjing, Jiangsu, China, 210029
Actively Recruiting
Research Team
N
Ningning Wang, Professor
CONTACT
L
Lianju Qin, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here